Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate using 5,10-methylenetetrahydrofolate (methylene-THF) as a cofactor. Additionally we are shipping Thymidylate Synthetase Proteins (18) and Thymidylate Synthetase Kits (15) and many more products for this protein.
Showing 10 out of 271 products:
Human Monoclonal TYMS Primary Antibody for IF, WB - ABIN393644
Kristensen, Pedersen, Melsen, Ellehauge, Mejer: Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. in The Journal of international medical research 2010
Show all 5 references for ABIN393644
Human Monoclonal TYMS Primary Antibody for EIA, IF - ABIN452662
Shahrokni, Rajebi, Saif: Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? in Clinical colorectal cancer 2009
Show all 3 references for ABIN452662
Human Polyclonal TYMS Primary Antibody for FM, IP - ABIN107487
Sohn, Croxford, Yates, Lucock, Kim: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. in Journal of the National Cancer Institute 2004
Show all 2 references for ABIN107487
Human Polyclonal TYMS Primary Antibody for EIA, IHC (fro) - ABIN2853636
Haqqani, Cowling, Maroun, Birnboim: Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens. in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1999
Cow (Bovine) Polyclonal TYMS Primary Antibody for WB - ABIN2783412
Ikeda, Sasazuki, Natsukawa, Shaura, Koizumi, Kasuga, Ohnami, Sakamoto, Yoshida, Iwasaki, Tsugane: Screening of 214 single nucleotide polymorphisms in 44 candidate cancer susceptibility genes: a case-control study on gastric and colorectal cancers in the Japanese population. in The American journal of gastroenterology 2008
Human Polyclonal TYMS Primary Antibody for FM, IP - ABIN2801851
Conradi, Bleckmann, Schirmer, Sprenger, Jo, Homayounfar, Wolff, Rothe, Middel, Becker, Ghadimi, Beissbarth, Liersch: Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment. in Annals of surgical oncology 2011
Possible interaction routes between hydrophobic residues of the mouse thymidylate synthase protein N-terminal segment and the active site are also discussed
SHMT1 (show SHMT1 Antibodies) and TYMS localization to the nucleus is essential to prevent uracil accumulation in DNA
Synergistic activation of the TATA-less thymidylate synthase promoter by the Ets transcription factor (show ELF2 Antibodies) GABP and Sp1 (show SP1 Antibodies).
downregulation of expression results in block of cell cycle expression when influenced by Fe65 (show APBB1 Antibodies)
posttranslationally-modified thymidylate synthase is associated with cell resistance to 5-fluoro-dUrd
This study identified a novel single repeat in the TYMS gene which might have an impact on the expression of this gene, which needs to be confirmed by functional studies.
There were no other associations between single -nucleotide polymorphisms and the efficacy of MTX (show MTX1 Antibodies) treatment. CONCLUSIONS: The MTHFR (show MTHFR Antibodies) 677CC and GGH (show GGH Antibodies) 401TT and CT genotypes were associated with a reduction in the number of MTX (show MTX1 Antibodies)-related adverse events.
Our findings emphasize the pivotal relevance of RNAi as an effective tool for increasing the therapeutic efficacy of PMX (show PRRX1 Antibodies), a cornerstone in the treatment regimens of Malignant mesothelioma thereby, raising the possibility for the development of a novel therapeutic strategy, combination therapy of TS-shRNA and PMX (show PRRX1 Antibodies), that can surpass many of the currently applied, but less effective, therapeutic regimens against lethal MPM.
treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC (show SRC Antibodies) retrospectively in a cohort of patients with non-small cell lung cancer, were evaluated.
TYMS gene amplification predicts outcome of patients receiving pemetrexed with advanced non-small cell lung cancer.
Thymidylate Synthase Polymorphisms are associated with the Risk of Lung Cancer.
Study suggests a novel function of HSP90 (show HSP90 Antibodies)-Src (show SRC Antibodies) pathway in regulation of TYMS expression and acquisition of 5-FU resistance in colon cancer.
The expression of thymidylate synthase and its correlation with survival in stage II/III gastric cancer patients
TYMS overexpression was detected in 61 % of non-small cell lung cancer patients and low expression in 39 %.
The study suggests that patients carrying rs183205964, a G>C substitution in the promoter enhancer region of TYMS, are at strongly increased risk of severe, potentially life-threatening, toxicity when treated with fluoropyrimidines.
Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate using 5,10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. Expression of this gene and that of a naturally occuring antisense transcript rTSalpha (GeneID:55556) vary inversely when cell-growth progresses from late-log to plateau phase.
, thymidylate synthase
, thymidylate synthetase
, thymidylate synthase-like